Close

CAR Complementary Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Complementary products are a type of product purchased with the main product and supplemented by its use. They were previously close to each other. Generally, complementary products are not sold and used alone. Creative Biolabs offers a range of CAR-related main products such as CAR vectors, CAR cells, CAR kits, etc. At the same time, Creative Biolabs has launched a series of complementary products to meet the experimental and project needs of our customers. These products can serve as a supplement or substitute for shortages.

Our CAR Complementary Products

Here are some complementary products Creative Biolabs provides:

Fig.1 The structure of CD3-X bispecific antibody. (Wikipedia https://en.wikipedia.org/wiki/Bi-specific_T-cell_engager#/media/File:Bi-specific_T-cell_engager.svg)

CAR CD3-X bispecific antibody primarily redirects T cells to specific tumor antigens and directly activates T cells to function. Creative Biolabs offers custom CAR CD3-X bispecific antibody, which typically target both tumor antigens and CD3 molecules. This CAR CD3-X bispecific antibody non-covalently binds CD3 molecules to TCRs and participates in antigen-specific signal transduction to induce T cell activation.

Fig.2 DNA structure. (Wikipedia https://en.wikipedia.org/wiki/Abalone_%28molecular_mechanics%29#/media/File:DNA-ligand-by-Abalone.png)

DMAb technology is a new method for the direct production and secretion of functional mAbs in vivo, delivering plasmids containing coding antibody sequences to tissues based on plasmid DNA delivery. Creative Biolabs utilizes DMAb technology to inject an engineered synthetic DMAb plasmid encoding IgG inserts directly into muscle and deliver them intracellular through electroporation, resulting in the expression and secretion of IgG in vivo. Creative Biolabs offers a wide range of DMAb products to enable in vivo delivery of highly effective monoclonal antibodies.

Fig.3 Monoclonal antibody. (Yang, et al., 2019)

TCR-like antibody is a novel antibody that can recognize tumor cell surface peptides/MHC complexes. It performs specific anti-tumor immunity through different molecular mechanisms. Creative Biolabs has developed a range of TCR antibody products against peptide/MHC complexes that are intended to be used as targets for engineered TCR-T cell therapy.

Fig.4 Mechanism of CAR detection reagents with flow cytometry. (Reichman, et al., 2022)

Accurate evaluation of the expression of CAR on T/NK immune cells has great significance for the discovery and clinical detection of CAR. Creative biolabs offers a wide range of CAR detection reagents to help you evaluate CAR expression. Our CAR products can be used to detect the manufacture of CART and analyze the persistence and expansion during CART cell therapy.

Fig.5 CAR structure. (Xia, et al., 2017)

As a leading global provider of products and services in the field of CAR, Creative Biolabs offers a wide range of consumables related to CAR in addition to vectors, viruses, and cells closely related to CAR.

Fig.6 CAR small-molecule compounds. (Gardner, et al., 2022)

In vitro CAR-T manufacturing, small molecule-mediated regulation of T cell differentiation can optimize the therapeutic effect of cellular immunotherapy. Studies have shown that many small molecules induce changes in protein and gene expression levels and affect cell proliferation and viability of T cell subsets. Creative Biolabs offers a wide range of small-molecule compounds that help enhance the therapeutic properties of CAR-T cells.

In addition to a comprehensive list of CAR products, Creative Biolabs offers global consulting services where our personnel are always available and can quickly resolve your questions. If you have any questions about CAR, please contact us immediately!

References

  1. Saleem, Ramsey.; et al. "Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product." Pharmaceutical research (2020) 37,6 114.
  2. Yang, Xiaofeng.; et al. "Opportunities and challenges for antibodies against intracellular antigens." Theranostics. (2019) 9,25 7792-7806.
  3. Reichman, Avinoam.; et al. "Comparison of FACS and PCR for detection of BCMA-CAR-T cells." International journal of molecular sciences. (2022) 23,2 903.
  4. Xia, An-Liang.; et al. "Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities." Oncotarget. (2017) 8,52 90521-90531.
  5. Gardner, T.J.; et al. Engineering CAR-T cells to activate small-molecule drugs in situ. Nat Chem Biol. (2022) 18, 216–225.
DNA-encoded mAb Products
TCR-Like Antibody Products
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.